Compass Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Compass Therapeutics has a total shareholder equity of $157.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $161.1M and $4.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$156.26m |
Equity | US$157.06m |
Total liabilities | US$4.08m |
Total assets | US$161.14m |
Recent financial health updates
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth
Jun 05We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely
Feb 13Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth
Sep 20Recent updates
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth
Jun 05We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely
Feb 13Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth
Sep 20Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial
Oct 11Financial Position Analysis
Short Term Liabilities: CMPX's short term assets ($158.6M) exceed its short term liabilities ($3.9M).
Long Term Liabilities: CMPX's short term assets ($158.6M) exceed its long term liabilities ($189.0K).
Debt to Equity History and Analysis
Debt Level: CMPX is debt free.
Reducing Debt: CMPX has no debt compared to 5 years ago when its debt to equity ratio was 41.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CMPX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CMPX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 8% each year